Resmed
RMD
$195.27
+1.76%
ResMed is a global leader in respiratory care devices, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. The company holds a dominant market position in the sleep apnea space, benefiting from structurally growing demand driven by aging populations, rising obesity rates, and increasing diagnosis rates. The current investor narrative centers on ResMed's digital health transformation and strategic acquisitions, such as the recent purchase of Noctrix Health, which aim to differentiate the company through clinical data integration and expand into adjacent therapeutic areas. However, the stock has faced significant headwinds from competitive pressures and market concerns about growth sustainability, leading to a sharp decline from its 52-week high.…
RMD
Resmed
$195.27
Related headlines
RMD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Resmed's 12-month outlook, with a consensus price target around $248.60 and implied upside of +27.3% versus the current price.
Average Target
$248.60
0 analysts
Implied Upside
+27.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$180 - $325
Analyst target range
ResMed is covered by 15 analysts, with a consensus recommendation of 'Buy' (mean rating 2.39 on a 1-5 scale where 1 is Strong Buy). The average price target is $248.60, implying 27.3% upside from the current price of $195.27. The distribution leans bullish, with 8 Buy ratings, 6 Hold, and 1 Sell. The target range spans from a low of $180.00 to a high of $325.00. The high target of $325 assumes a successful digital health transformation and margin expansion, while the low target of $180 reflects risks from competitive pressures and slower growth. Recent rating actions show some caution: Citigroup downgraded from Buy to Neutral in July 2026, and Morgan Stanley downgraded from Overweight to Equal Weight in June 2026. However, Mizuho and RBC Capital maintain Outperform ratings, indicating mixed sentiment. The wide spread between low and high targets ($145) signals high uncertainty about the company's future trajectory, which is typical for a stock undergoing a significant transition.
Bulls vs Bears: RMD Investment Factors
ResMed presents a classic value-versus-growth debate. On the bull side, the company boasts accelerating revenue growth (10.8% YoY), expanding margins (gross margin 62.2%), robust free cash flow ($1.748B TTM), and a forward P/E of 16.2x that is cheap relative to the industry. On the bear side, the stock has declined 28.6% over the past year, carries high short interest (9.46 days), and has seen analyst downgrades. The trailing P/E of 27.0x is a premium to peers. The single most important tension is whether the company can sustain its recent growth acceleration and margin expansion to justify the forward earnings expectations. If it does, the stock could re-rate higher; if not, further downside toward the 52-week low of $180 is possible. Currently, the evidence slightly favors the bull case given the strong fundamental performance and attractive forward valuation, but the market's skepticism warrants caution.
Bullish
- Strong Revenue Growth Acceleration: ResMed's Q3 FY2026 revenue grew 10.8% YoY to $1.431B, accelerating from 4.4% in the year-ago quarter and 10.6% in Q2. This marks the fastest growth in recent quarters, driven by the Sleep and Respiratory segment and Residential Care Software.
- Expanding Margins and Profitability: Gross margin improved to 62.2% in Q3 FY2026 from 59.3% a year ago, while operating margin rose to 34.9% from 33.0%. Net margin reached 27.9%, well above the medical devices industry average of ~15%, demonstrating strong operational efficiency.
- Robust Free Cash Flow Generation: Trailing twelve-month free cash flow is $1.748B, representing a 4.6% FCF yield. This cash generation supports organic investments, strategic acquisitions like Noctrix Health, and shareholder returns via dividends and buybacks.
- Attractive Forward Valuation: The forward P/E of 16.2x is at a 26% discount to the industry average of 22x, and near the low end of its 5-year historical range (20x-50x). This suggests the market is pricing in a sharp earnings rebound, offering upside if growth materializes.
Bearish
- Significant Stock Price Decline: The stock has fallen 28.6% over the past year, underperforming the S&P 500 by 45.1%. The current price of $195.27 is near the 52-week low of $180.27, reflecting deep market pessimism about growth sustainability.
- Elevated Short Interest: The short ratio of 9.46 days indicates high bearish sentiment, with many investors betting against the stock. This could signal fundamental concerns or competitive pressures that are not yet fully priced in.
- Analyst Downgrades and Mixed Sentiment: Recent downgrades from Citigroup (Buy to Neutral) and Morgan Stanley (Overweight to Equal Weight) highlight growing caution. While the consensus is still Buy, the average target of $248.60 implies only 27.3% upside, and the low target of $180 suggests downside risk.
- Premium Trailing Valuation: The trailing P/E of 27.0x is 23% above the medical devices industry average of 22x. This premium may be hard to justify if growth decelerates or margins face pressure from competition or rising costs.
RMD Technical Analysis
ResMed is in a sustained downtrend, with the stock price declining 28.6% over the past year. The current price of $195.27 sits at 66.5% of its 52-week range ($180.27 low to $293.81 high), indicating it is closer to the low end. This positioning suggests the market is pricing in significant negative sentiment, but also raises the possibility of a value opportunity if fundamentals stabilize. The 1-year relative strength versus SPY is -45.1%, confirming severe underperformance. Short-term momentum shows a mixed picture: the 1-month price change is -0.6%, while the 3-month change is -11.2%, indicating continued weakness but with a potential deceleration in the pace of decline. The 1-month relative strength versus SPY is -1.4%, suggesting the stock is roughly moving in line with the market recently, a divergence from the longer-term trend that could signal a potential bottoming process. However, the 3-month relative strength of -14.7% still reflects persistent selling pressure. The 52-week low of $180.27 provides key support, while the 52-week high of $293.81 is a major resistance level. A breakdown below $180 could trigger further downside, while a move above $294 would signal a trend reversal. The stock's beta of 0.775 indicates it is less volatile than the overall market, meaning the recent sharp decline is more company-specific than macro-driven. The short ratio of 9.46 days suggests elevated bearish sentiment, which could fuel a short squeeze if positive catalysts emerge.
Beta
0.78
0.78x market volatility
Max Drawdown
-37.8%
Largest decline past year
52-Week Range
$180-$294
Price range past year
Annual Return
-28.6%
Cumulative gain past year
| Period | RMD Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +1.4% |
| 3m | -11.2% | +3.3% |
| 6m | -22.6% | +6.3% |
| 1y | -28.6% | +16.0% |
| ytd | -20.2% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RMD Fundamental Analysis
ResMed's revenue trajectory remains solidly growing, with the most recent quarterly revenue (Q3 FY2026 ending March 31, 2026) reaching $1.431 billion, up 10.8% year-over-year. This marks an acceleration from the prior quarter's 10.6% growth and the 4.4% growth in the year-ago quarter, indicating a strengthening top-line trend. The growth is driven by the Sleep and Respiratory segment ($1.256 billion) and Residential Care Software ($167 million), with the latter representing a high-growth digital health component. The company is highly profitable, with net income of $398.7 million in Q3 FY2026, translating to a net margin of 27.9%. Gross margin expanded to 62.2% from 59.3% in the prior year quarter, reflecting favorable product mix and operational efficiencies. Operating margin also improved to 34.9% from 33.0% a year ago, demonstrating strong cost control. ResMed boasts a fortress balance sheet with a debt-to-equity ratio of just 0.14 and a current ratio of 3.44, indicating ample liquidity. Free cash flow generation is robust, with trailing twelve-month FCF of $1.748 billion, representing a FCF yield of 4.6% based on the current market cap. Return on equity (ROE) stands at 23.5%, well above the medical devices industry average, underscoring efficient capital allocation. The company's strong cash flow supports both organic investments and strategic acquisitions, such as the recent Noctrix Health purchase for $340 million.
Quarterly Revenue
$1.4B
2026-03
Revenue YoY Growth
+10.8%
YoY Comparison
Gross Margin
62.3%
Latest Quarter
Free Cash Flow
$1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RMD Overvalued?
Given ResMed's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 27.0x, while the forward P/E is 16.2x, implying the market expects significant earnings growth in the coming year. This gap suggests that the current price already reflects anticipated earnings improvements, leaving little room for error. Compared to the medical devices industry average P/E of approximately 22x, ResMed's trailing P/E of 27.0x represents a 23% premium. However, the forward P/E of 16.2x is at a 26% discount to the industry forward average of 22x, indicating that the market is pricing in a sharp earnings rebound. This discount may be justified by ResMed's superior profitability (net margin of 27.9% vs. industry average of ~15%) and strong free cash flow generation. Historically, ResMed's trailing P/E has ranged from 20x to 50x over the past five years. The current 27.0x is near the lower end of that range, suggesting the stock is relatively cheap compared to its own history. This could indicate a value opportunity if the company can deliver on growth expectations, but it also reflects the market's skepticism about near-term headwinds.
PE
27.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ResMed's balance sheet is strong with a debt-to-equity ratio of only 0.14 and a current ratio of 3.44, indicating low financial risk. However, the company's net margin of 27.9% is high but could compress if input costs rise or pricing power weakens. The trailing P/E of 27.0x implies that the market expects continued earnings growth; any shortfall could lead to multiple contraction. Free cash flow of $1.748B TTM is robust, but the company's reliance on the Sleep and Respiratory segment for ~88% of revenue creates concentration risk. A slowdown in sleep apnea device sales could significantly impact cash flows.
Market & Competitive Risks: ResMed's stock has a beta of 0.775, indicating lower market correlation, but the 28.6% decline over the past year shows company-specific risk. The medical devices industry is competitive, with Philips and others vying for market share. The recent downgrades from Citigroup and Morgan Stanley suggest that some analysts see limited near-term upside. Regulatory risks include potential changes in sleep apnea diagnosis guidelines or reimbursement policies. The stock's short ratio of 9.46 days indicates elevated bearish sentiment, which could exacerbate downside if negative news emerges.
Worst-Case Scenario: In a worst-case scenario, ResMed could face a combination of slower revenue growth (e.g., below 5%), margin compression from competitive pricing, and a broader market sell-off. This could drive the stock to the analyst low target of $180, representing a 7.8% decline from the current price of $195.27. However, if the company's fundamentals deteriorate more severely, the stock could test its 52-week low of $180.27, a 7.7% drop. Historically, the maximum drawdown is -37.76%, which would imply a price of ~$121.50, but this is unlikely given the company's strong cash flows and market position. Realistically, an investor could lose up to 10-15% in a moderate adverse scenario.